ENPP2 and neoplasm: Given ATX's superior predictive ability over conventional tumor and fibrosis markers, patients with elevated ATX (≥ 1.323 mg/L) may benefit from more intensive post‐RFA surveillance due to their substantially higher recurrence risk (HR: 6.38–10.50).